TITLE

WHAT THE STUDIES SHOW ABOUT ADHERENCE

PUB. DATE
November 2010
SOURCE
Pediatric Nursing;Nov2010 Supplement, p10
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses a data from the 2000 to 2004 Palivizumab Outcomes Registry that included over 19,500 infants with congenital heart disease receiving palivizumab prophylaxis. According to the report, adherence to the injection schedule increased over a four year period and palivizumab use for the prevention of respiratory syncytial virus (RSV) was consistent with revised American Academy of Pediatrics (AAP) guidelines.
ACCESSION #
58103355

 

Related Articles

  • CASE STUDY 2: IS MATT ELIGIBLE FOR PALIVIZUMAB PROPHYLAXIS?  // Pediatric Nursing;Nov2010 Supplement, p7 

    The article presents a case study of a full-term level 2 male infant who was auscultated by an intern and found to have no heart beat despite the fact the baby was pink and moving. Several diagnostic tests were performed, including an cardiac echocardiogram, that revealed situs inversus totalis...

  • PALIVIZUMAB REDUCES RSV HOSPITALIZATION.  // Pediatric Nursing;Nov2010 Supplement, p8 

    The article discusses two multicenter, placebo-controlled randomized trials that confirmed the efficacy of palivizumab in preventing respiratory syncytiai virus (RSV) infection in infants. Statistics related to the treatment outcome of infants on palivizumab compared to those on a placebo are...

  • JOURNAL CLUB. IS IMMUNOPROPHYLAXIS AGAINST RSV INFECTIONS COST EFFECTIVE? Burke, Michael // Contemporary Pediatrics;Aug2011, Vol. 28 Issue 8, p28 

    In this article the author discusses a study which revealed the exceeded savings due to the prevented cost of the respiratory syncytial virus (RSV) infection-related hospitalizations with palivizumab. He mentions the inefficacy of the study and encourages considering other effective...

  • A Broadly Neutralizing Human Monoclonal Antibody Exhibits In Vivo Efficacy Against Both Human Metapneumovirus and Respiratory Syncytial Virus. Schuster, Jennifer E.; Cox, Reagan G.; Hastings, Andrew K.; Boyd, Kelli L.; Wadia, Jay; Chen, Zhifeng; Burton, Dennis R.; Williamson, R. Anthony; Williams, John V. // Journal of Infectious Diseases;Jan2015, Vol. 211 Issue 2, p216 

    Background Human metapneumovirus (HMPV) is a leading cause of acute respiratory tract infection, with significant morbidity and mortality. No licensed vaccines or therapeutic agents exist. Monoclonal antibodies (mAbs) are effective at preventing other infectious diseases and could be used...

  • Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus. Empey, Kerry M.; Peebles Jr, R. Stokes; Kolls, Jay K. // Clinical Infectious Diseases;5/1/2010, Vol. 50 Issue 9, p1258 

    Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV). Palivizumab is a monoclonal antibody for the prevention of RSV in high-risk children. Ribavirin is approved for treatment of severe RSV disease; however, its effectiveness in improving outcomes is...

  • Palivizumab for RSV prevention in high-risk children.  // PharmacoEconomics & Outcomes News;1/27/2007, Issue 520, p3 

    The article discusses research being done on the use of palivizumab in preventing respiratory syncytial virus infections in high-risk children. It references a study by M. J. C. Nuijten et al published in a 2007 issue of "PharmacoEconomics." According to researchers, palivizumab would add more...

  • Palivizumab Compliance by Infants in Puerto Rico During the 2009-2010 Respiratory Syncytial Virus Season. Matías, Israel; García-García, Inés; García-Fragoso, Lourdes; Valcárcel, Marta // Journal of Community Health;Dec2014, Vol. 39 Issue 6, p1040 

    Respiratory syncytial virus (RSV) is the leading viral pathogen responsible for bronchiolitis and pneumonia in infants. We assessed palivizumab prophylaxis compliance for infants in Puerto Rico. We retrospectively studied data from 868 infants (409 females, 459 males) during the 2009-2010 RSV...

  • Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age. Malkin, Elissa; Yogev, Ram; Abughali, Nazha; Sliman, Joseph; Wang, C. Kathy; Zuo, Fengrong; Yang, Chin-Fen; Eickhoff, Mark; Esser, Mark T.; Tang, Roderick S.; Dubovsky, Filip // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Despite substantial morbidity associated with respiratory syncytial virus (RSV) infection, there is no licensed vaccine. MEDI-559 is a live attenuated intranasal vaccine candidate being developed for prevention of lower respiratory illness due to RSV in young children. This randomized,...

  • Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety. BONIFAZI, MARTINA; ROSSI, MARTA; MOJA, LORENZO; SCIGLIANO, VINCENZO DAVIDE; FRANCHI, MATTEO; LA VECCHIA, CARLO; ZOCCHETTI, CARLO; NEGRI, EVA // Oncologist;Jan2012, Vol. 17 Issue 1, p117 

    The aim of this study was to describe the clinical use of bevacizumab in Lombardy (9.5 million inhabitants), Italy, during 2006 -2007 in patients with metastatic colorectal cancer (mCRC) to evaluate compliance with the Italian Medicine Agency (AIFA) indications, the incidence of adverse events,...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics